Connect with us


Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Reveals 2018 Clinical And Corporate Update



Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced that it will focus on rare and near-rare neurological and psychiatric disorders that have the highest unmet medical needs. The company also intends to expand its ZYN002 in Phase 2/3 program that outlines the Fragile X syndrome (FXS) and Phase 2 programs to assess the refractory epilepsies conditions including the adult refractory focal epilepsy and other developmental and epileptic encephalopathies (DEE) found in pediatric and adolescent patients.

In addition, the company plans to launch Phase 2 development of ZYN001 in Tourette syndrome by end of the year. The resolution to focus on the rare and near-rare neurological and psychiatric disorders is basically due to a variety of essential factors such as the forceful ZYN002 clinical data seen in the Fragile X syndrome and the refractory focal epilepsy, according to Armando Anido, Chairman and CEO of Zynerba.

Concentrating on both rare and near-rare strategy also allows the company to maximize on both ZYN001 and ZYN002 with the possibility of improving the product pricing across all indications. Anido believes that Zynerba is well positioned to execute on its new strategy, since it has sufficient capital to fund all the required operations up to 2019.

The next big cannabis story to hit North America is Phoenix Life Science International (PLSI), traded in the US, but with the largest global production based in the tropics and a license to distribute worldwide. Take a look at Phoenix Life Science International PLSI), Its currently trading under $18 dollars per share on the OTC markets. Learn More Now!

Zynerba is looking forward to deliver several corporate and clinical achievements that could be significant to its stakeholders including the investors and patients. According to Anido, 2018 seems to be a year of great evolution for the company. The firm also intends to gather significant data from the ongoing open-label extension studies in both the Fragile X syndrome and adult refractory focal epilepsy that would be published by end of the year.

Zynerba is one of the pharmaceutical companies that operate with a zero-debt on its balance sheet. Hence the company has the capability to maximize on its capital returns by increasing its debt since it has low cost of capital. However, the company must adhere to the strict debt obligations that could potentially reduce its financial flexibility.

Pushing the barriers for global distribution, Phoenix Life Science International (PLSI) is the next cannabis play. Just think Canopy x 100, that is how big their plantation in the tropics will be. No lights, no green houses, just maximum growth + minimal cost = home run. Learn More Now!


Learn More About PLSI at your brokerage today!




Cronos Group Inc. (NASDAQ:CRON) Pops On Altria Acquisition Talk After Q3 Net Loss Disappointment

Cronos Group Inc. (NASDAQ:CRON) is skyrocketing up the charts having emerged it is an acquisition target of Marlboro cigarette-maker Altria...

Business6 days ago

American Green Inc (OTCMKTS:ERBB) Kicks Off December On Rough Patch

American Green Inc (OTCMKTS:ERBB) seems to have started the month of December on a rather dull pace after closing the...

Business2 months ago

The Sales Growth Trend Persists for PotNetwork Holdings Inc (OTCMKTS:POTN)

PotNetwork Holdings Inc (OTCMKTS:POTN) is perhaps THE juggernaut CBD story, aside from CVSI, over the past 12 months. That is...

Business2 months ago

Hemp Inc (OTCMKTS:HEMP) Looks to Garner Support on Expansion and CBD Talk

Hemp Inc (OTCMKTS:HEMP) shares recently slipped under technical support in the $0.025. The stock has possibly found some bids in...


How to View the Current Action in Hemp Inc (OTCMKTS:HEMP)

One stock that has started to key on potential support in a lateral range is Hemp Inc (OTCMKTS:HEMP). The stock...


Near-Term Headwinds Hit Scotts Miracle-Gro Co (NYSE:SMG) With A Huge Impact

Bank of America Corp (NYSE:BAC) has disclosed that Scotts Miracle-Gro Co (NYSE:SMG) has lately been experiencing several near term risks....


Argitek Holdings Inc (OTCMKTS:AGTK) To Focus On Acquisition, Revenues & Profitability In 2018

Argitek Holdings Inc (OTCMKTS:AGTK) recently revealed that in 2018, the company’s main focus will be the acquisition, revenues, and profitability....


PharmaCyte Biotech Inc (OTCMKTS:PMCB) Completes Pore Size Studies & 29 Tests Useful In Pancreatic Cancer Therapy

PharmaCyte Biotech Inc (OTCMKTS:PMCB) has said that the cells it is planning to use in the clinical trial in patients...


Puration Inc (OTCMKTS:PURA) To Apply For Canadian Recreational Cannabis Cultivation License; To Give EVERx CBD Sports Water Free Samples

Puration Inc (OTCMKTS:PURA) recently announced that it will be applying for the Canadian recreational cannabis cultivation license. The confirmation came...


Marijuana Company Of America Inc (OTCMKTS:MCOA)’s JV Completes 10,000 Sq. Ft. Greenhouse Set up; Provides Update on Oregon Project

Marijuana Company Of America Inc (OTCMKTS:MCOA) recently announced that its Joint Venture with Bougainville Ventures Inc. based in Washington has...


Create a future where the human body can repair, restore, and rejuvenate itself


Trading Symbol


The Next Big Global Cannabis Play